All News

A new blood test for adults as young as 40 years arrives as employers and insurers still treat Alzheimer disease as an old-age condition.

Itch and skin appearance outranked safety for 300 US adults with chronic hand eczema, but cancer risk came next.

Rebisufligene etisparvovec-hopf (Fayuvi; Ultragenyx) is a 1-time gene therapy that addresses the underlying cause of Sanfilippo syndrome type A.

Systematic review finds no ready blood biomarkers for psoriasis biologics, but IL-17A/IL-17F and beta-defensin 2 show promise for precision medicine.

Claims data show regorafenib is prescribed earlier than guidelines advise for a good share of patients with advanced GIST, with dosing also varying widely.

Oral GLP-1s, Medicare access, and lingering weight bias are reshaping obesity care, says NYU Langone's Holly Lofton, MD.

Activated memory B cells were already enriched at treatment end in the 5 of 21 patients who later cleared HBsAg

Specialty pharmacy leaders will gather in National Harbor for inSPire2026, tackling cell and gene therapy access, AI, and high-cost drug pricing.

ERS spotlights AI lung disease detection; employer cancer benefits; outpatient CAR T; tafasitamab response similar across races; HFpEF missed at referral.

Each additional hour of nightly CPAP use was associated with 13% lower all-cause mortality risk in a French cohort of adults with sleep apnea.

A 20-year Danish registry study found higher antidepressant and anxiolytic use among women with endometriosis, both before and after diagnosis.

An Endocrine Society scientific statement argues percent weight loss is an inadequate measure of obesity treatment success and proposes new targets.

Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.

Ultimately, causality could not be established due to lack of data on disease severity and socioeconomic status, among others.

GRADE meta-analysis: hepatitis A vaccine blocks 96% in pre-exposure vaccination; outbreak response uses millions of doses, but post-exposure prophylaxis evidence is weak.

Alcohol abuse was the strongest post-trauma psychiatric predictor of cardiovascular events, with mood disorders more prominent among women.

A systematic review finds people with narcolepsy and idiopathic hypersomnia often stay employed but face work impairment and limited workplace support.

Finerenone is the first new FDA-approved treatment in more than 30 years for adults with CKD associated with type 1 diabetes.

ASCOLT finds no overall adjuvant aspirin benefit in colorectal cancer, but meta-analysis links improved disease-free survival to PIK3CA exon 9/20 mutations.

IL-23 inhibitor risankizumab outperforms TYK2 inhibitor deucravacitinib for PASI 90 in biologic-naive moderate plaque psoriasis.

Dupilumab cut hand eczema severity (59.8% vs 15.2% with placebo), regardless of a patient's atopic history.

Christos Vaklavas, MD, discussed barriers limiting rural oncology access and challenges to adopting resource-intensive therapies.

Keith Kaye, MD, MPH, breaks down the institutional gaps, from antibiotic overuse to hand hygiene fatigue, that let Clostridioides difficile persist.

FDA cut required monitoring for tarlatamab’s first 2 doses from 22-24 hours to 6-8 hours, easing a barrier to community cancer care.

Shiven B. Patel, MD, MBA, shares strategies for closing biomarker testing gaps, including for patients with non–small cell lung cancer.

The ESC's 2026 heart failure guidelines overhaul HF classification, rename therapy categories, and add a new HFpEF recommendation.

The FDA cleared PrecivityAD2, a blood test from C2N Diagnostics that helps diagnose Alzheimer disease in adults as young as 40.

Reference countries have limited room to simply raise their own drug budgets to absorb the pressure, the lead study author explains.